1. ALLA AKTIER
  2. NYHETER
  3. LIDDS

LIDDS

Nyheter LIDDS Nyheter alla bolag
Slipp dessa annonser och få en massa andra godsaker med vårt premiumabonnemang.

LIDDS’ Annual Report 2023 published

MARKN.

GOTHENBURG, SWEDEN – The 2023 Annual report of LIDDS AB (publ) is now available on the company website.

The annual report is available in Swedish in PDF format on the company website at: https://liddspharma.com/en/investors/financial-reports/.

Copies can be ordered from LIDDS AB, PO Box 12040, 112 40 Stockholm or by e-mail: info@liddspharma.com.

For additional information, please contact

Jenni Björnulfson, CEO and CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’ Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. LIDDS offers the NanoZolid technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. The company is listed on Nasdaq First North Growth market.

Attachments

LIDDS Årsredovisning 2023 FINAL

Datum 2024-05-06, kl 15:05
Källa MFN
Bifogade filer
LIDDS Årsredovisning 2023 FINAL